- $38.91m
- $31.88m
- $1.12m
Annual cashflow statement for RenovoRx, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -6.32 | -9.89 | -10.2 | -8.81 | -11.2 |
| Depreciation | |||||
| Non-Cash Items | 0.673 | 0.65 | -0.631 | -0.591 | 0.44 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.265 | 0.428 | 0.605 | 0.28 | -0.247 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -5.92 | -8.81 | -10.3 | -9.13 | -11 |
| Capital Expenditures | -0.015 | 0 | — | -0.012 | -0.002 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -2.03 | 2.03 | — | — |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.015 | -2.03 | 2.03 | -0.012 | -0.002 |
| Financing Cash Flow Items | 0 | — | — | — | -1.3 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 19.3 | 0.042 | 5.01 | 15.1 | 10.8 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 13.4 | -10.8 | -3.22 | 5.98 | -0.13 |